Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data

BMC Endocrine Disorders

Volumn 12, Issue , 2012, Pages

  Bonds, Denise E ^a   Miller, Michael E ^b   Dudl, Jim ^c   Feinglos, Mark ^d   Ismail Beigi, Faramarz ^e   Malozowski, Saul ^f   Seaquist, Elizabeth ^g   Simmons, Debra L ^h   Sood, Ajay ^e  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c KAISER PERMANENTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Hypoglycemia; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; INSULIN; METFORMIN; REPAGLINIDE; SULFONYLUREA;

ANXIETY; ARTICLE; BLURRED VISION; CLINICAL TRIAL (TOPIC); CONFUSION; DISORIENTATION; DIZZINESS; FATIGUE; FOOD INTAKE; HEADACHE; HOSPITALIZATION; HUMAN; HUNGER; HYPOGLYCEMIA; IRRITABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; SWEATING; TACHYCARDIA; UNCONSCIOUSNESS;

EID: 84861543332     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-12-5     Document Type: Article

References (18)

1. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005, 22(6):749-755. 10.1111/j.1464-5491.2005.01501.x, 15910627.
2. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003, 26(4):1176-1180. 10.2337/diacare.26.4.1176, 12663593.
3. Johnson ES, Koepsell TD, Reiber G, Stergachis A, Platt R. Increasing incidence of serious hypoglycemia in insulin users. J Clin Epidemiol 2002, 55(3):253-259. 10.1016/S0895-4356(01)00479-6, 11864796.
4. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008, 31(11):2086-2091. 10.2337/dc08-1171, 2571051, 18782901.
5. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99(12A):21i-33i.
6. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
7. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362(17):1563-1574. 2879499, 20228404.
8. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362(17):1575-1585.
9. Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F, Feeney P. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007, 99(12A):34i-43i.
10. Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JV, Fonseca VA, Hall K, Hramiak I, Miller ME, et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007, 99(12A):80i-89i.
11. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010, 340:b5444. 10.1136/bmj.b5444, 2803743, 20061360.
12. Deary IJ, Hepburn DA, MacLeod KM, Frier BM. Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia 1993, 36(8):771-777. 10.1007/BF00401150, 8405746.
13. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey. Diabet Med 2006, 23(7):750-756. 10.1111/j.1464-5491.2006.01880.x, 16842479.
14. Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab 2010, 95(5):2240-2247. 10.1210/jc.2009-2828, 20305006.
15. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, et al. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. Ann Intern Med 2011, 154:602-613.
16. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf 2009, 32(5):409-418. 10.2165/00002018-200932050-00004, 19419235.
17. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002, 51(9):2796-2803. 10.2337/diabetes.51.9.2796, 12196473.
18. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 2004, 27(11):2585-2589. 10.2337/diacare.27.11.2585, 15504990.